Ruler of Ras Al Khaimah, UAE, Says ‘Science is the Bedrock Upon Which We Build a Sustainable Future’ During Opening Address at 16th International Workshop on Advanced Materials
17.2.2025 16:05:00 CET | Business Wire | Press release
HH Sheikh Saud bin Saqr Al Qasimi:‘Ras Al Khaimah is committed to nurturing scientific advancement and contributing to the global conversation on advanced materials’
His Highness Sheikh Saud bin Saqr Al Qasimi, UAE Supreme Council Member and Ruler of Ras Al Khaimah, delivered an opening keynote address on the first day of the three-day International Workshop on Advanced Materials (IWAM), where he talked of science holding the key to building a more sustainable world and of how Ras Al Khaimah is committed to scientific advancement.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250217844634/en/

His Highness Sheikh Saud bin Saqr Al Qasimi, UAE Supreme Council Member and Ruler of Ras Al Khaimah, delivering the opening keynote address at the International Workshop on Advanced Materials today (Photo: AETOSWire)
HH Sheikh Saud said: “Through the annual hosting of IWAM, Ras Al Khaimah is reaffirming its commitment to nurturing scientific advancement and contributing to the global conversation on advanced materials.
“By developing a culture of scientific enquiry and investing in advanced materials, we are laying the foundation for a brighter tomorrow. Major breakthroughs in advanced materials research have the potential to revolutionize energy production, transportation and manufacturing.”
Science is the systematic and purposeful pursuit of knowledge, the lens through which we examine the universe, HH Sheikh Saud added.
“Science must be the bedrock upon which we build a sustainable and prosperous future, with our younger generations playing an active role in furthering our pursuit of knowledge,” HH Sheikh Saud concluded.
IWAM, in its 16th year, brings together 200+ attendees from 20+ countries, including scientists, students and speakers, for lectures, discussions and poster sessions on how advanced materials are helping to shape the future.
The forum is attended by scientists from prestigious academic institutions, such as the universities of Cambridge and Oxford (UK), and the University of California and Massachusetts Institute of Technology (MIT) (U.S.).
IWAM also sees scientists awarding the student winners of the Ras Al Khaimah Innovation and Sustainability Challenge, which comprises seven competitions to develop innovative solutions to real-life challenges.
A scientific session for high-school students also takes place during IWAM, while scientists will visit Ras Al Khaimah-based companies to highlight how advanced materials can be utilized to improve productivity.
IWAM is sponsored by Ras Al Khaimah’s Stevin Rock, one of the largest quarrying companies in the world, with a production capacity of 80 million+ tons per year.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20250217844634/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
Seoul Viosys Eyes the $60 Billion AI Data Center Optical Communication Market with Opto Semiconductors27.4.2026 15:00:00 CEST | Press release
Joint Development Talks with Global Optical Communications companiesExpanding Partnerships to Provide Total Transceiver Solution1,800 Patents Secured for High-Performance Optical Communications Seoul Viosys (KOSDAQ: 092190), a company specializing in opto-semiconductor devices, is accelerating its entry into the next-generation photonics market supported by its proprietary “No-wire” and “No-package” fundamental patents—essential technologies for micrometer (μm)-scale miniaturization of opto-semiconductors—as well as its competitiveness in VCSEL technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426926495/en/ Seoul Viosys Optoelectronic Semiconductor Structure Subject to a Permanent U.S. Injunction in February 2026, Covering Similar Products and Employees (Image: Seoul Viosys) As the rapid expansion of AI drives a paradigm shift in data centers from copper-based to optical-based architectures, the company is streng
vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 14:51:00 CEST | Press release
Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom